Junior Research Prize 2009 for Neuromuscular Diseases is awarded by Temmler Pharma
Published April 28th, 2009
The Junior Research Prize has been awarded to Gabriela-Elena Oprea from the Institute for Human Genetics in Cologne, in line with the 19th Congress of the Scientific Advisory Council of the German Society for Muscular Diseases. Dr. Oprea received this award for her innovative discovery of a protective gene in spinal muscular atrophy (SMA). The €2,500 prize, which has already been awarded for six years, is funded by Temmler Pharma for the research of rare neuromuscular diseases.eases.
Spinal muscular atrophy (SMA) is one of the most frequently occurring recessive, genetic diseases in human beings; characterized by the degeneration of the motor neurons in the spinal cord. This causes a symmetrical weakening of the muscles and atrophy of the leg, arm and eventually the entire torso musculature. This genetic disease has lead to early childhood death in many cases. Dr. Oprea’s extraordinary research has made it possible to identify a fully protective modified gene for an inherited disease for the first time. In addition, a significant contribution has been made to better understanding spinal muscular atrophy (SMA).
The discovery of a protective gene gives scientists and patients across the world hope that therapeutic treatments for this often deadly disease will soon be discovered.
In the central nervous system sector, supplements for rare neurological diseases, such as Huntington’s disease and Myasthenia gravis, are sold alongside generics. By awarding the Junior Research Prize, Temmler Pharma is making a significant contribution to researching these and other diseases, which are often neglected due to the small number of patients affected by them.
By successfully combining innovative technology and comprehensive services, Temmler would like to open up new market potential for our customers in the health care sector, thereby providing them with notable competitive advantages.
Temmler offers services across the entire contract manufacturing process, and thereby ensures a seamless transition between the individual stages of value-adding. From development to production to worldwide distribution, comprehensive services have been developed which cover virtually all requirements in the pharmaceutical contract manufacturing market.
Temmler Pharma GmbH & Co. KG
Temmlerstr. 2
D-35039 Marburg
GERMANY
E-Mail: info@temmler.eu
Web: www.temmler.eu
